1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)
Public ClinicalTrials.gov record NCT00929110. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 52-week Treatment, Randomized, Double-blind, Placebo-controlled, With Open-label Tiotropium, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Patients With Chronic Obstructive Pulmonary Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study was designed to investigate the 1 year efficacy and safety of the 50 µg once daily (od) dose of glycopyrronium bromide (NVA237) in patients with moderate to severe chronic obstructive pulmonary disease.
Study identification
- NCT ID
- NCT00929110
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,066 participants
Conditions and interventions
Conditions
Interventions
- Glycopyrronium bromide Drug
- Placebo to glycopyrronium bromide Drug
- Tiotropium Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2009 (Type not available)
- Primary completion
- Apr 2011 (Actual)
- Completion
- Apr 2011 (Actual)
- Last update posted
- Aug 17, 2012
2009 – 2011
United States locations
- U.S. sites
- 75
- U.S. states
- 34
- U.S. cities
- 71
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Birmingham | Alabama | 35249 | — |
| Novartis Investigative Site | Mobile | Alabama | 36608 | — |
| Novartis Investigative Site | Montgomery | Alabama | 36117 | — |
| Novartis Investigator Site | Fort Smith | Arkansas | 72901 | — |
| Novartis Investigator Site | Anaheim | California | 92801 | — |
| Novartis Investigative Site | Fullerton | California | 92835 | — |
| Novartis Investigative Site | Lakewood | California | 90712-151 | — |
| Novartis Investigator Site | Los Angeles | California | 90025 | — |
| Novartis Investigator Site | Los Angeles | California | 90048 | — |
| Novartis Investigator Site | Mission Viejo | California | 92691 | — |
| Novartis Investigator Site | Paramount | California | 90723 | — |
| Novartis Investigator Site | Riverside | California | 92506 | — |
| Novartis Investigative Site | Rolling Hills Estates | California | 90274 | — |
| Novartis Investigator Site | San Diego | California | 92120 | — |
| Novartis Investigator Site | Colorado Springs | Colorado | 80907 | — |
| Novartis Investigative site | DeLand | Florida | 32720 | — |
| Novartis Investigative Site | Fort Lauderdale | Florida | 33316-192 | — |
| Novartis Investigative Site | Miami | Florida | 33186 | — |
| Novartis Investigative Site | Miami Beach | Florida | 33140 | — |
| Novartis Investigative Site | Ocala | Florida | 34471 | — |
| Novartis Investigative Site | Panama City | Florida | 32405 | — |
| Novartis Investigative Site | Tampa | Florida | 33606 | — |
| Novartis Investigator Site | Winter Park | Florida | 32789 | — |
| Novartis Investigative Site | Atlanta | Georgia | 30322 | — |
| Novartis Investigative Site | Blue Ridge | Georgia | 30513 | — |
| Novartis Investigative Site | Duluth | Georgia | 30096 | — |
| Novartis Investigator Site | Coeur d'Alene | Idaho | 83814 | — |
| Novartis Investigator Site | Skokie | Illinois | 60076 | — |
| Novartis Investigator Site | New Albany | Indiana | 47150-3054 | — |
| Novartis Investigator Site | Valparaiso | Indiana | 46383 | — |
| Novartis Investigator Site | Council Bluffs | Iowa | 51503-4658 | — |
| Novartis Investigator Site | Iowa City | Iowa | 52240 | — |
| Novartis Investigator Site | Shawnee | Kansas | 66216-1800 | — |
| Novartis Investigative Center | Crescent Springs | Kentucky | 41017 | — |
| Novartis Investigative Site | Crestview Hills | Kentucky | 41017-542 | — |
| Novartis Investigative Site | Hazard | Kentucky | 41701 | — |
| Novartis Investigative Site | Louisville | Kentucky | 40215 | — |
| Novartis Investigator Site | Lafayette | Louisiana | 70508 | — |
| Novartis Investigator Site | Sunset | Louisiana | 70584 | — |
| Novartis Investigator Site | Boys Town | Maine | 68010 | — |
| Novartis Investigative Site | Columbia | Maryland | 21044 | — |
| Novartis Investigative Site | Wheaton | Maryland | 20902 | — |
| Novartis Investigative Site | North Dartmouth | Massachusetts | 02747 | — |
| Novartis Investigative Site | Taunton | Massachusetts | 02780 | — |
| Novartis Investigator Site | Minneapolis | Minnesota | 55402 | — |
| Novartis Investigator Site | St Louis | Missouri | 63122 | — |
| Novartis Investigator Site | Bozeman | Montana | 59718 | — |
| Novartis Investigator Site | Lincoln | Nebraska | 68510 | — |
| Novartis Investigator Site | Omaha | Nebraska | 68131-2197 | — |
| Novartis Investigator Site | Papillion | Nebraska | 68046 | — |
| Novartis Investigative Site | Skillman | New Jersey | 08558 | — |
| Novartis Investigative Site | Endwell | New York | 13760 | — |
| Novartis Investigative site | Charlotte | North Carolina | 28207 | — |
| Novartis Investigator Site | Cincinnati | Ohio | 45245 | — |
| Novartis Investigator Site | Sylvania | Ohio | 43560 | — |
| Novartis Investigator Site | Toledo | Ohio | 43614 | — |
| Novartis Investigator Site | Oklahoma City | Oklahoma | 73103 | — |
| Novartis Investigator Site | Oklahoma City | Oklahoma | 73112 | — |
| Novartis Investigator Site | Medford | Oregon | 97504-8741 | — |
| Novartis Investigator Site | Medford | Oregon | 97504 | — |
| Novartis Investigator Site | Portland | Oregon | 92713 | — |
| Novartis Investigator Site | Portland | Oregon | 97213 | — |
| Novartis Investigative Site | Downingtown | Pennsylvania | 19335-2620 | — |
| Novartis Investigative Site | Philadelphia | Pennsylvania | 19115 | — |
| Novartis Investigative Site | East Providence | Rhode Island | 02914 | — |
| Novartis Investigative Site | Providence | Rhode Island | 02906 | — |
| Novartis Investigative Site | North Charleston | South Carolina | 29406 | — |
| Novartis Investigator Site | Austin | Texas | 78750 | — |
| Novartis Investigator Site | El Paso | Texas | 79902 | — |
| Novartis Investigator Site | New Braunfels | Texas | 78130-6113 | — |
| Novartis Investigator Site | San Antonio | Texas | 78229 | — |
| Novartis Investigator Site | Provo | Utah | 84604-1584 | — |
| Novartis Investigative Site | Charlottesville | Virginia | 22908 | — |
| Novartis Investigator Site | Tacoma | Washington | 98405-4266 | — |
| Novartis Investigator Site | Milwaukee | Wisconsin | 53209 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00929110, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 17, 2012 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00929110 live on ClinicalTrials.gov.